IBJNews

Lilly continues string of positive trials

Back to TopCommentsE-mailPrint

Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results with results from experimental cancer and diabetes drugs.

The Indianapolis-based drugmaker said Monday its experimental diabetes drug dulaglutide lowered blood sugar in Type 2 diabetics better than three existing diabetes drugs in three Phase 3 clinical trials.

And on Oct. 15, Lilly announced that its cancer drug ramucirumab helped extend survival times for stomach cancer patients in a Phase 3 trial.

The results, when combined with the positive signs Lilly reported from its Alzheimer’s drug solanezumab, present an encouraging pattern that the company’s pipeline-driven strategy may, in fact, have a shot at succeeding. Its a stark reversal from a series of clinical trial failures that Lilly suffered this summer.

“This is great news for the pipeline, which continues the recent news on sola, ramucirumab and bariticinib,” UBS pharmaceutical analyst Marc Goodman said in a note to investors Monday. Baricitinib is another Lilly drug aimed at rheumatoid arthritis.

Investors have had similar thoughts, bidding up Lilly shares 24 percent over the past two months.

But Lilly still has a bit of proving to do. Its Alzheimer’s drug most likely will need to go through another Phase 3 clinical trial before it can win approval from regulators.

Meanwhile, the diabetes drug dulaglutide has to show that it is superior to Bydureon, a similar once-weekly injectable medicine already on the market. Both dulaglutide and Bydureon are known as glucagon-like peptides, or GLP-1 drugs. In 2005, Lilly helped launch the first GLP medicine, Byetta, in partnership with California-based Amylin Pharmaceuticals Inc. The two companies also launched Bydureon, which is a once-weekly version of Byetta, last year.

Patients receiving once-weekly injections of dulaglutide saw their levels of hemoglobin A1C—a key measure of blood sugar—go down more than did patients in the trials taking metformin, Byetta or Januvia.

But how much the levels went down, Lilly isn’t saying. Lilly said it would present more data about dulaglutdie during medical conferences in 2013 and 2014. Lilly plans to file for regulatory approval of dulagrlutide next year.

In its clinical trials, Bydureon also produced lower levels of blood sugar than either Byetta or Januvia, which is a popular oral diabetes medicine made by New Jersey-based Merck & Co. Inc.

Lilly gave up rights to both Byetta and Bydureon last year after a dispute with its former partner on the drugs, California-based Amylin Pharmaceuticals Inc. Lilly received a $250 million break-up fee, and royalties up to $1.2 billion over the life of Byetta.

"We're very encouraged by the results to date from our Phase III dulaglutide trials and are pleased to be one step closer to offering a new GLP-1 treatment option for Type 2 diabetes," Enrique Conterno, president of Lilly’s diabetes division, said in a prepared statement.

And as for the cancer drug ramucirumab, Lilly’s clinical trial data only showed that its drug was better than “best supportive care,” not better than another cancer drug. Lilly is still running a clinical trial that compares ramucirumab against an old cancer drug, paclitaxel.

Results from that second Phase 3 trial are expected a year from now.

“Ramu news encouraging but we need to see more data,” is how Morgan Stanley analyst David Risinger headlined his research note on the drug’s clinical trial results.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. So the Mayor adds another non value added layer to having a vehicle towed? Whereby the City Government RECIEVES AN ILLEGAL KICKBACK FROM A LGOISTICS COMPANY THAT SUBS THE WORK TO LOCAL TOW COMPANIES? What is the service the City performs for receiving the "tribute"? This is RICO!!!!! What a corrupt and unnecessary layer. What a dirtbag Mayor and his cronies.

  2. Owner occupied housing. Clear enough?

  3. So people think I am paranoid. It's from experience in dealing with puds requested by developers who make major donations themselves to representatives, have nice fund raisers for those running for office and hide through pac's. then there are the public relation firms. You will note some pr comments below. You there Clyde Lee? My opinion. Commercial along 421, great. Multifamily housing, terrible idea that will change the town. Senior condos or zero lot line homes west, great. I suggest keeping all entries to commercial areas at 421. All entries to owner occupied on sycamore. Will keep the traffic on sycamore down some. Two other things. You can't trust what will be there in 10 years. Steve builds quality stuff, but areas change over time. Look at the changes at the wall mart center at 86th and 421 over the last 10 years. Look at the apartments and neighborhoods behind St Vincent's. Raintree properties WILL decrease in value if commercial and multifamily goes in near. It has already been happening around the bridges area. The houses that have been sold recently are way below market. Several deals not closed due to the Illinois construction and the whole unsurety of the bridges. It's pretty simple, Zionsville will approve the whole thing because the city council has been groomed over a LONG period of time for this. I might even suggest some are in their position as a result of this.

  4. Esta, do you have a dog in this fight? You seem to really want to knock anyone against this project. No, I didn't move to Indiana for the architecture. I moved here for that red barn in the field. The horses and fields of corn. A place that is NOT overdeveloped. There are plenty of nearby places in Indianapolis that could be REDEVELOPED instead.

  5. RKW - OK, we get it, you're paranoid. The question is, are you paranoid enough? Greg - Yes, Pittman(s) is (are) at it again. They are developers, they build things. It's what they do. So when you go to work tomorrow, Greg, you're at it again too. Cliff - Really? You moved to Indiana for its progressive architecture? That's like moving to England for the cuisine. Zionsvillain - The house you moved to was once a field or woods. I'm willing to bet folks were upset when that ground was plowed under and a house was built. But I guess now that you are in, everything should stop? "My house was OK, but the next one is sprawl." SE Guy - Please don't paint us with such a wide brush. Most reasonable Zionsville residents welcome planned, measured development.

ADVERTISEMENT